1
|
Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C, Ferraro TN, Hakonarson H, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Doyle GA, Lohoff FW, Berrettini WH. Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend 2013; 127:122-8. [PMID: 22795689 PMCID: PMC3509227 DOI: 10.1016/j.drugalcdep.2012.06.023] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2012] [Revised: 06/18/2012] [Accepted: 06/21/2012] [Indexed: 11/27/2022]
Abstract
BACKGROUND Addiction susceptibility and treatment responsiveness are greatly influenced by genetic factors. Sequence variation in genes involved in the mechanisms of drug action have the potential to influence addiction risk and treatment outcome. The opioid receptor system is involved in mediating the rewarding effects of cocaine and opioids. The μ-opioid receptor (MOR) has traditionally been considered the primary target for opioid addiction. The MOR, however, interacts with and is regulated by many known MOR interacting proteins (MORIPs), including the δ-opioid receptor (DOR). METHODS The present study evaluated the contribution of OPRD1, the gene encoding the DOR, to the risk of addiction to opioids and cocaine. The association of OPRD1 polymorphisms with both opioid addiction (OA) and cocaine addiction (CA) was analyzed in African American (OA n=336, CA n=503) and European American (OA n=1007, CA n=336) populations. RESULTS The primary finding of this study is an association of rs678849 with cocaine addiction in African Americans (allelic p=0.0086). For replication purposes, this SNP was analyzed in a larger independent population of cocaine addicted African Americans and controls and the association was confirmed (allelic p=4.53 × 10(-5); n=993). By performing a meta-analysis on the expanded populations, the statistical evidence for an association was substantially increased (allelic p=8.5 × 10(-7)) (p-values non-FDR corrected). CONCLUSION The present study suggests that polymorphisms in OPRD1 are relevant for cocaine addiction in the African American population and provides additional support for a broad role for OPRD1 variants in drug dependence.
Collapse
Affiliation(s)
- R C Crist
- Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Clarke TK, Ambrose-Lanci L, Ferraro TN, Berrettini WH, Kampman KM, Dackis CA, Pettinati HM, O'Brien CP, Oslin DW, Lohoff FW. Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction. Genes Brain Behav 2012; 11:415-23. [PMID: 22443215 DOI: 10.1111/j.1601-183x.2012.00785.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Genetic factors are believed to account for 30-50% of the risk for cocaine and heroin addiction. Dynorphin peptides, derived from the prodynorphin (PDYN) precursor, bind to opioid receptors, preferentially the kappa-opioid receptor, and may mediate the aversive effects of drugs of abuse. Dynorphin peptides produce place aversion in animals and produce dysphoria in humans. Cocaine and heroin have both been shown to increase expression of PDYN in brain regions relevant for drug reward and use. Polymorphisms in PDYN are therefore hypothesized to increase risk for addiction to drugs of abuse. In this study, 3 polymorphisms in PDYN (rs1022563, rs910080 and rs1997794) were genotyped in opioid-addicted [248 African Americans (AAs) and 1040 European Americans (EAs)], cocaine-addicted (1248 AAs and 336 EAs) and control individuals (674 AAs and 656 EAs). Sex-specific analyses were also performed as a previous study identified PDYN polymorphisms to be more significantly associated with female opioid addicts. We found rs1022563 to be significantly associated with opioid addiction in EAs [P = 0.03, odds ratio (OR) = 1.31; false discovery rate (FDR) corrected q-value]; however, when we performed female-specific association analyses, the OR increased from 1.31 to 1.51. Increased ORs were observed for rs910080 and rs199774 in female opioid addicts also in EAs. No statistically significant associations were observed with cocaine or opioid addiction in AAs. These data show that polymorphisms in PDYN are associated with opioid addiction in EAs and provide further evidence that these risk variants may be more relevant in females.
Collapse
Affiliation(s)
- T-K Clarke
- Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, 125 South 31st Street, Philadelphia, PA 19104, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Dundon WD, Pettinati HM, Lynch KG, Xie H, Varillo KM, Makadon C, Oslin DW. The therapeutic alliance in medical-based interventions impacts outcome in treating alcohol dependence. Drug Alcohol Depend 2008; 95:230-6. [PMID: 18329827 PMCID: PMC2600892 DOI: 10.1016/j.drugalcdep.2008.01.010] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2007] [Revised: 01/08/2008] [Accepted: 01/09/2008] [Indexed: 11/17/2022]
Abstract
This study examined the relationship of the therapeutic alliance and treatment outcomes for alcohol-dependent patients receiving naltrexone or placebo and one of three different types of clinical interventions, including two medical-based (non-specialty) treatments. This is a secondary analysis of a 24-week randomized, placebo-controlled, clinical trial of 100mg/day of naltrexone or placebo for patients with DSM-IV alcohol dependence. Patients were also randomized to one of three interventions: (1) medication clinic only, (2) medication clinic plus BRENDA (an intervention promoting pharmacotherapy), or (3) medication clinic plus cognitive behavioral therapy (CBT). Early in treatment, patients and clinicians completed the working alliance inventory (WAI). Regression analyses were conducted to determine the predictive validity of the WAI on percent days abstinent and percent of sessions attended over the clinical trial. In the medication clinic only condition, the clinicians' WAI total score was marginally correlated to percent of visits attended (p=.057) but not percent days abstinent. In the medication clinic plus BRENDA condition, clinicians' WAI total score was positively correlated with percent days abstinent (p=.013) but not percent visits attended. No significant relationships were found between the WAI scores and either outcome measure in the CBT condition or for any of the patient rated assessments. To our knowledge, this is the first published report providing some support for the importance of the therapeutic alliance in medical interventions for alcohol dependence but only in the context of the clinicians' ratings. The absence of other effects underscores the need for further research.
Collapse
Affiliation(s)
- W D Dundon
- Center for the Studies of Addiction, Department of Psychiatry, University of Pennsylvania School of Medicine, 3900 Chestnut Street, Philadelphia, PA 19104-6178, USA.
| | | | | | | | | | | | | |
Collapse
|
4
|
Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2002; 10:258-68. [PMID: 11579624 DOI: 10.1080/105504901750532148] [Citation(s) in RCA: 152] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
Abstract
Naltrexone has repeatedly been shown to reduce drinking in alcohol-dependent patients. Previous clinical research suggests that naltrexone may be more effective at reducing drinking among patients with high levels of alcohol craving at the beginning of treatment. In addition, laboratory studies suggest that naltrexone may be more efficacious among patients with a high familial loading of alcohol problems. We explored both of these possibilities in the context of the first 12-week phase of a double blind, placebo-controlled naltrexone trial. A total of 121 patients were randomized to receive 100 mg/day naltrexone and 62 patients were randomized to receive placebo. Both naltrexone and placebo were given in conjunction with a psychosocial intervention designed to be integrated with the use of pharmacotherapy. This intervention was administered by nurse practitioners. Overall, patients randomized to naltrexone reported drinking five or more drinks on fewer days than did placebo controls (p = .04). Interactions were observed between medication group assignment and both craving level prior to randomization (p = .02) and family loading of alcohol problems (p = .05). In both cases, the interaction was in the predicted direction. These data suggest that patients with high levels of alcohol craving or a strong family history of alcoholism are more likely to benefit from naltrexone treatment.
Collapse
Affiliation(s)
- J R Monterosso
- Center for the Study of Addictions, Department of Psychiatry, University of Pennsylvania, Philadelphia, Philadelphia Veteran Affairs Medical Center, USA
| | | | | | | | | | | | | |
Collapse
|
5
|
Pettinati HM. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry 2001; 62 Suppl 20:26-31. [PMID: 11584872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
The usefulness of selective serotonin reuptake inhibitors (SSRIs) to treat alcohol dependence continues to be a subject of debate. Most recently, investigations have tried to predict whether a given patient will respond to SSRIs in terms of reducing excessive alcohol drinking. The subtyping of alcohol-dependent individuals has ranged from relatively simple classifications (e.g., presence of comorbid depression) to more complex classifications (e.g., potential to have abnormalities in serotonin [5-HT] neurotransmission). Although only a few studies have been completed, results thus far indicate that alcoholic subgroups are differentially responsive to 5-HT pharmacotherapy with respect to drinking-related outcomes. In addition, there are preliminary results encouraging the use of SSRIs in combination with other medications for treating alcohol dependence in patients with and without comorbid psychiatric disorders. Information from these studies is promising, suggesting the need for further investigation.
Collapse
Affiliation(s)
- H M Pettinati
- Center for the Study of Addictions, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia Veterans Affairs Medical Center, USA
| |
Collapse
|
6
|
Abstract
Clinical studies that have evaluated serotonergic medications to reduce alcohol consumption have yielded conflicting results. These studies primarily treated patients with alcohol dependence, excluding those with a current depressive disorder, in an effort to differentiate any medication effects directly on drinking from those on mood. Yet despite the exclusion of current depression, a group of alcohol-dependent patients who are not depressed can be highly heterogeneous. For example, this subgroup can include those with a lifetime depressive disorder. If these patients were more sensitive to serotonergic medications than patients without a lifetime depressive disorder, medication effects in a subgroup of patients who were not depressed could be obscured. Thus, the purpose of this study was to examine the efficacy of sertraline for treating alcohol dependence in patient groups that were differentiated by the presence or absence of lifetime depression. This study examined the effectiveness of sertraline (200 mg/day) or placebo for 14 weeks in 100 alcohol-dependent subjects with (N = 53) or without (N = 47) a lifetime diagnosis of comorbid depression. Sertraline treatment seemed to provide an advantage in reducing drinking in alcohol-dependent patients without lifetime depression, illustrated best with a measure of drinking frequency during treatment. However, sertraline was no better than placebo in patients with a diagnosis of lifetime comorbid depression, and current depression did not change the results. Treatment with selective serotonin reuptake inhibitors may be useful in alcohol-dependent patients who are not depressed. Subtyping those with alcohol dependence on the basis of the absence versus the presence of a lifetime depressive disorder may help to resolve conflicting findings in the literature on the treatment of alcohol dependence with serotonergic medications.
Collapse
Affiliation(s)
- H M Pettinati
- Center for the Study of Addictions, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA.
| | | | | | | | | | | |
Collapse
|
7
|
Pettinati HM, Pierce JD, Belden PP, Meyers K. The relationship of Axis II personality disorders to other known predictors of addiction treatment outcome. Am J Addict 2001; 8:136-47. [PMID: 10365194 DOI: 10.1080/105504999305947] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
Abstract
This study evaluated the prevalence of Axis II disorders in substance abuse patients and the relationship between Axis II psychopathology and two other known predictors of adverse addiction treatment outcomes, i.e., Axis I psychiatric comorbidity and illegal drug use, specifically cocaine. 232 patients with cocaine and/or alcohol dependence were admitted to either inpatient or outpatient addiction recovery programs at Carrier Foundation, a nonprofit, private-pay hospital in New Jersey. Axis II disorders were more prevalent in cocaine than alcohol dependence and in patients with Axis I psychiatric comorbidity. When all three predictors were evaluated in one prediction model, the combination of Axis I and II psychopathology was the best predictor of a return to substance use at one year post-treatment, compared to the three factors alone. These findings highlighted the importance of the interrelationship of the relative prognostic value of three known predictors of addiction treatment.
Collapse
Affiliation(s)
- H M Pettinati
- Department of Psychiatry, University of Pennsylvania, Philadelphia, USA.
| | | | | | | |
Collapse
|
8
|
Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001; 285:1299-307. [PMID: 11255384 DOI: 10.1001/jama.285.10.1299] [Citation(s) in RCA: 391] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
CONTEXT Electroconvulsive therapy (ECT) is highly effective for treatment of major depression, but naturalistic studies show a high rate of relapse after discontinuation of ECT. OBJECTIVE To determine the efficacy of continuation pharmacotherapy with nortriptyline hydrochloride or combination nortriptyline and lithium carbonate in preventing post-ECT relapse. DESIGN Randomized, double-blind, placebo-controlled trial conducted from 1993 to 1998, stratified by medication resistance or presence of psychotic depression in the index episode. SETTING Two university-based hospitals and 1 private psychiatric hospital. PATIENTS Of 290 patients with unipolar major depression recruited through clinical referral who completed an open ECT treatment phase, 159 patients met remitter criteria; 84 remitting patients were eligible and agreed to participate in the continuation study. INTERVENTIONS Patients were randomly assigned to receive continuation treatment for 24 weeks with placebo (n = 29), nortriptyline (target steady-state level, 75-125 ng/mL) (n = 27), or combination nortriptyline and lithium (target steady-state level, 0.5-0.9 mEq/L) (n = 28). MAIN OUTCOME MEASURE Relapse of major depressive episode, compared among the 3 continuation groups. RESULTS Nortriptyline-lithium combination therapy had a marked advantage in time to relapse, superior to both placebo and nortriptyline alone. Over the 24-week trial, the relapse rate for placebo was 84% (95% confidence interval [CI], 70%-99%); for nortriptyline, 60% (95% CI, 41%-79%); and for nortriptyline-lithium, 39% (95% CI, 19%-59%). All but 1 instance of relapse with nortriptyline-lithium occurred within 5 weeks of ECT termination, while relapse continued throughout treatment with placebo or nortriptyline alone. Medication-resistant patients, female patients, and those with more severe depressive symptoms following ECT had more rapid relapse. CONCLUSIONS Our study indicates that without active treatment, virtually all remitted patients relapse within 6 months of stopping ECT. Monotherapy with nortriptyline has limited efficacy. The combination of nortriptyline and lithium is more effective, but the relapse rate is still high, particularly during the first month of continuation therapy.
Collapse
Affiliation(s)
- H A Sackeim
- Department of Biological Psychiatry, New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Pettinati HM, Rukstalis MR, Luck GJ, Volpicelli JR, O'Brien CP. Gender and psychiatric comorbidity: impact on clinical presentation of alcohol dependence. Am J Addict 2001; 9:242-52. [PMID: 11000920 DOI: 10.1080/10550490050148071] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
We examined differences in clinical presentation for outpatient alcohol treatment in: 1) males and females, considering comorbidity; and 2) three comorbid groups, considering gender. Drinking indices and emotional, physical, and sexual abuse reports were compared in 127 male and 69 female alcohol-dependent patients who have a current (36.2%) or lifetime (20.4%) psychiatric disorder or who never had a psychiatric disorder (43.4%). Females reported more emotional and physical abuse than males. Females reported drinking smaller volumes of alcohol but on more days than males. All with current comorbidity, irrespective of gender, reported more days of heavy drinking than other groups. When evaluating drinking status, gender and comorbidity should be considered.
Collapse
Affiliation(s)
- H M Pettinati
- Department of Psychiatry, University of Pennsylvania, Philadelphia 19104, USA.
| | | | | | | | | |
Collapse
|
10
|
Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000; 24:1041-9. [PMID: 10924008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
BACKGROUND Characteristic behaviors of some alcohol-dependent individuals, e.g., binge drinking, comorbid psychopathology, and some types of alcohol-related problems, have been linked to abnormalities in serotonergic neurotransmission. However, studies that have evaluated serotonergic pharmacotherapy for reducing drinking have yielded conflicting results. One explanation for these findings is a general failure to distinguish alcohol subgroups that may be differentiated on the basis of serotonergic abnormalities. However, in 1996, Kranzler and colleagues reported that Type B alcoholics, who are characterized by high levels of premorbid vulnerability, alcohol dependence severity, and comorbid psychopathology, showed less favorable drinking outcomes in response to treatment with fluoxetine, a serotonin reuptake inhibitor, than with placebo. This medication effect was not seen in Type A alcoholics, i.e., those with lower risk/severity of alcoholism and psychopathology. The aim of the present study was to explore the validity of differential responding by alcohol-dependent subtypes using the serotonin reuptake inhibitor, sertraline. METHODS A k-means clustering procedure was applied to a sample of alcohol-dependent subjects enrolled in a 14-week, placebo-controlled trial of 200 mg/day of sertraline, classifying them into lower-risk/severity (Type A: n = 55) and higher-risk/severity (Type B: n = 45) subgroups. RESULTS A significant interaction between alcoholic subtype and medication condition was found, confirming the findings of Kranzler and colleagues that alcoholic subtypes responded differentially to serotonergic medication. Somewhat at variance with their results, however, the present study showed that the lower risk/severity (Type A) subjects had more favorable outcomes when treated with sertraline compared to placebo. CONCLUSIONS Alcoholic subtypes differentially responded to sertraline when used as a treatment to reduce alcohol drinking, with one subtype having more favorable outcomes. Subtyping alcoholics may help to resolve conflicting findings in the literature on serotonergic treatment of alcohol dependence.
Collapse
Affiliation(s)
- H M Pettinati
- Center for the Study of Addictions, Department of Psychiatry, University of Pennsylvania School of Medicine, and the Philadelphia Veterans Affairs Medical Center, 19104-6178, USA.
| | | | | | | | | | | |
Collapse
|
11
|
Pettinati HM, Volpicelli JR, Pierce JD, O'Brien CP. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 2000; 19:71-83. [PMID: 10772604 DOI: 10.1300/j069v19n01_06] [Citation(s) in RCA: 90] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The effectiveness of naltrexone, a FDA-approved medication for alcohol dependence, can be improved if we support and help patients to consistently take their medication. We illustrate how patient noncompliance with treatment negatively affects outcome, and, we describe a new intervention to enhance medication compliance. Outcome was evaluated for 196 alcohol dependent outpatients who were treated with 50 mg/day naltrexone or placebo for 12 weeks. For patients who adhered to the prescribed treatment, relapse rates were lower with naltrexone than placebo (10% vs. 38.6%, p < 0.001). For noncompliant patients, relapse rates were high and comparable between naltrexone- and placebo-treated patients (42.9% vs. 40%). In a second study of 100 alcohol dependent outpatients, we introduced an intervention that resulted in better medication compliance rates compared to a previous naltrexone study of patients who did not receive the intervention (77.0% vs. 60.8%, p < 0.01). This provided some support for the use of an intervention that targets medication compliance when prescribing naltrexone.
Collapse
Affiliation(s)
- H M Pettinati
- Department of Psychiatry, University of Pennsylvania, The Philadelphia Medical Center for Veteran Affairs, USA
| | | | | | | |
Collapse
|
12
|
Pettinati HM, Meyers K, Evans BD, Ruetsch CR, Kaplan FN, Jensen JM, Hadley TR. Inpatient alcohol treatment in a private healthcare setting: which patients benefit and at what cost? Am J Addict 1999; 8:220-33. [PMID: 10506903 DOI: 10.1080/105504999305839] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
This study investigated whether selected patients have better outcomes with inpatient than outpatient treatment. There were 93 inpatients and 80 outpatients with alcohol dependence who were evaluated at treatment entry to a private healthcare setting. Patients with multiple drinking-related consequences were less likely to return to significant drinking in the first 3 months after treatment ended if they had attended inpatient compared to outpatient treatment. Thus, inpatient appeared to have some advantage over outpatient treatment in the early recovery period for patients with multiple drinking-related consequences. The gap between inpatient and outpatient costs was also reduced when computed as a cost-effectiveness ratio, although treatment costs continued to remain proportionally higher with inpatient than outpatient treatment.
Collapse
Affiliation(s)
- H M Pettinati
- Department of Psychiatry, University of Pennsylvania, Philadelphia 19104-6178, USA.
| | | | | | | | | | | | | |
Collapse
|
13
|
|
14
|
Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 1999; 23:1289-95. [PMID: 10470970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
BACKGROUND This study introduces the Penn Alcohol Craving Scale (PACS), which has been used in several clinical trials at the University of Pennsylvania's Treatment Research Center. The PACS is a five-item, self-report measure that includes questions about the frequency, intensity, and duration of craving, the ability to resist drinking, and asks for an overall rating of craving for alcohol for the previous week. Each question is scaled from 0 to 6. METHODS To examine the questionnaire's psychometric properties, we sampled responses from 147 individuals participating in a 9-month combined natrexone (100 mg/day)/psychotherapy trial. The psychotherapy consisted of weekly sessions of nurse-administered medication compliance and supportive treatment. RESULTS The PACS proved to have excellent internal consistency. Predictive validity was demonstrated via a logistic regression analysis of craving during the 2nd week of the study on alcohol relapse during weeks 3-12 of the trial. Construct validity of the PACS was demonstrated via its convergence with two commonly used measures for assessing craving, the Obsessive Compulsive Drinking Scale and the Alcohol Urge Questionnaire. Lack of correlation between PACS scores and several other noncraving, self-report measures indicates that the PACS also had good discriminant validity. Additional analyses revealed that there were significant differences in craving scores during the initial 3 weeks of the trial among those who did and those who did not relapse during weeks 3-12. CONCLUSION The PACS is a reliable and valid measure of alcohol craving and can predict which individuals are at risk for subsequent relapse.
Collapse
Affiliation(s)
- B A Flannery
- Department of Psychiatry, University of Pennsylvania, Philadelphia 19104, USA.
| | | | | |
Collapse
|
15
|
Oslin DW, Pettinati HM, Volpicelli JR, Wolf AL, Kampman KM, O'Brien CP. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat 1999; 16:163-7. [PMID: 10023615 DOI: 10.1016/s0740-5472(98)00039-7] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Concurrent dependence on cocaine and alcohol is common among patients seeking addiction treatment. This study was undertaken to explore the effectiveness of naltrexone (150 mg) as a potential treatment for patients who are alcohol and cocaine dependent. Of 15 subjects enrolled in the 12-week, open medication trial, 7 subjects did not complete the study. Relapse to clinically significant drinking occurred in 7 subjects (47%). There was a reduction in the average daily amount of alcohol consumed from pretreatment to treatment (p < .001) and the percentage of days engaged in drinking behavior (p < .001). Similarly, there was a reduction in the average weekly amount spent on cocaine from pretreatment to treatment (p = .001) and the percentage of days using cocaine (p < .001). This preliminary study suggests that naltrexone (150 mg) may be tolerable in patients dependent upon alcohol and cocaine and may be effective in reducing both cocaine and alcohol use. The results of this study provide a rationale for a double-blind placebo-controlled study of the efficacy of naltrexone in this difficult to treat but prevalent population.
Collapse
Affiliation(s)
- D W Oslin
- Department of Psychiatry, University of Pennsylvania, Philadelphia, USA.
| | | | | | | | | | | |
Collapse
|
16
|
Oslin DW, Pettinati HM, Luck G, Semwanga A, Cnaan A, O'Brien CP. Clinical correlations with carbohydrate-deficient transferrin levels in women with alcoholism. Alcohol Clin Exp Res 1998; 22:1981-5. [PMID: 9884141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Carbohydrate-deficient transferrin (CDT) has received increasing attention as a potential biological marker for heavy drinking or as an objective marker of relapse in patients who are treated for alcohol dependence. Previous studies have demonstrated the utility of CDT among men, but there are fewer and inconsistent reports on the utility of CDT among women. This study reports in a sample of 40 alcohol-dependent women, the association between CDT levels, and several different types of measures of drinking intensity including frequency of heavy drinking. Although the majority of drinking indices correlated with CDT levels in men, among women, CDT levels were significantly correlated with the percentage of days of heavy drinking when heavy drinking day was defined as drinking 6 or more drinks per drinking day. The results also support an association between current menstrual function, CDT levels, and drinking indices. These findings suggest that the pattern of drinking (combining high frequency and high intensity) may be an important determinant of CDT levels in women with alcohol dependence, compared with men.
Collapse
Affiliation(s)
- D W Oslin
- Center for the Study of Addictions, Department of Psychiatry, University of Pennsylvania, Philadelphia Veterans Affairs Medical Center, 19104, USA
| | | | | | | | | | | |
Collapse
|
17
|
Gariti PW, Alterman AI, Ehrman RN, Pettinati HM. Reliability and validity of the aggregate method of determining number of cigarettes smoked per day. Am J Addict 1998; 7:283-7. [PMID: 9809132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Abstract
The authors evaluated the reliability of two pretreatment assessments (screening and intake) of cigarettes smoked per day (CPD) by the commonly used aggregate method. The validity of the aggregate method was also determined by comparison with results of the timeline followback (TLFB) method for the identical periods. The study participants were 49 outpatients undergoing nicotine patch treatment. The reliability of the two aggregate method evaluations of CPD was quite high by Pearson product-moment correlation (r) and good when based on the intraclass correlation. Correspondence between the CPD assessments based on the aggregate and TLFB methods for the two time-points ranged from fair (screening) to good (intake). Overall, the study findings indicate that the aggregate method provides reasonably consistent data.
Collapse
Affiliation(s)
- P W Gariti
- Philadelphia Veterans Affairs Medical Center/University of Pennsylvania School of Medicine, USA
| | | | | | | |
Collapse
|
18
|
Pettinati HM, Pierce JD, Wolf AL, Rukstalis MR, O'Brien CP. Gender differences in comorbidly depressed alcohol-dependent outpatients. Alcohol Clin Exp Res 1997; 21:1742-6. [PMID: 9438541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
UNLABELLED Clinical profiles of alcohol-dependent male and female outpatients were evaluated at treatment entry to compare the level of clinical severity in alcoholics with a coexistent comorbid depressive disorder to alcoholics who have never been depressed. Due to a higher proportion of females than males in the depressed alcoholic population, selected patient groups were oversampled to create a study group with equivalent number of males and females with and without comorbid depression. Clinical severity was assessed by examining both the extent of alcohol problems, and depressive symptomatology at treatment entry with respect to gender differences (unrelated to depression), effects of comorbid depression (unrelated to gender), and effects from the interaction of gender and depression. There were 93 DSM-III-R alcohol-dependent outpatients (50 males, 43 females), half of whom had a current or lifetime DSM-III-R depressive disorder. The amount of drinking in the 90 days before treatment entry, the degree of alcohol severity, and the number of lifetime drinking-related consequences were collected in the first week after detoxification. Diagnoses of lifetime and current depression were determined via the Structured Clinical Interview for DSM-III-R, and depressive symptoms were evaluated with rating scales 1 week after detoxification. In most cases, a depressive disorder was diagnosed only if sometime in the patient's history depressive symptoms had either predated problem drinking or been present during a 6-month abstinent period. RESULTS depressed males had a more severe clinical profile with respect to their alcoholism (i.e., more drinking, drinking-related problems, and alcohol severity than depressed females and never-depressed males). Surprisingly, females who had never been depressed (also no family history of depression) reported drinking the same quantities of alcohol in the 90 days before treatment and had comparable alcohol severity and number of consequences as males who had never been depressed. Depressed females, however, were more severely depressed (i.e., reported more intensive depressive symptoms than depressed male alcoholics). Thus, determining the type and extent of clinical severity at treatment entry in comorbidly depressed alcoholics depends on the gender of the patient The significant interaction between gender and the presence of comorbid depression that was found in this study may have important implications for predicting success in treatment.
Collapse
Affiliation(s)
- H M Pettinati
- Center for the Study of Addictions, Department of Psychiatry, University of Pennsylvania, Philadelphia 19104-6178, USA
| | | | | | | | | |
Collapse
|
19
|
Mulsant BH, Haskett RF, Prudic J, Thase ME, Malone KM, Mann JJ, Pettinati HM, Sackeim HA. Low use of neuroleptic drugs in the treatment of psychotic major depression. Am J Psychiatry 1997; 154:559-61. [PMID: 9090348 DOI: 10.1176/ajp.154.4.559] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE The adequacy of pharmacologic treatment received by patients with psychotic major depression was evaluated. METHOD The authors systematically assessed the pharmacotherapy received by 187 depressed patients before initiation of ECT and compared the medication trials of those with psychotic (N = 53) and nonpsychotic (N = 134) depression. RESULTS Despite a median of four medication trials and median index episode duration of 20 weeks, only two (4%) of the patients with psychotic depression received at least one adequate pharmacotherapy trial. In contrast, 70 (52%) of the patients with nonpsychotic depression received at least one adequate trial. Twenty-five (47%) of the patients with psychotic depression received either no neuroleptic treatment (N = 11) or treatment for less than 3 weeks (N = 14). Only eight (15%) received a daily neuroleptic dose higher than 200 mg of chlorpromazine equivalents. CONCLUSIONS These findings suggest that many patients with psychotic major depression referred for ECT receive inadequate pharmacotherapy because of either the absence or the inadequate use of neuroleptic medication.
Collapse
Affiliation(s)
- B H Mulsant
- Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh, PA, USA
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Saini RS, Pettinati HM, Semwanga AE, O'Brien CP. Carbohydrate-deficient transferrin: an investigative biochemical marker of heavy alcohol consumption. Psychopharmacol Bull 1997; 33:171-5. [PMID: 9133771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Carbohydrate-deficient transferrin (CDT) has been identified as a potential biochemical marker of heavy alcohol consumption. Published studies to date primarily have focused on the ability of CDT levels to distinguish individuals with heavy alcohol drinking from nondrinking populations. In contrast, this study examines the utility of CDT levels in distinguishing alcohol-dependent patients who drink heavily from those who drink smaller amounts. This study also evaluates the potential relationship of CDT to severity of alcohol dependence and its gender differences. Serum was collected in 38 DSM-III-R alcohol-dependent outpatients at treatment entry (22 males, 16 females). CDT levels correlated with the extent of alcohol drinking in the month before treatment in males (r = 0.56, df = 20, p < .01), but not in females (r = 0.08, df = 14, NS). CDT levels also correlated with alcohol severity at pre-treatment in males (r = 0.53, df = 20, p < .05), but not in females (r = 0.27, df = 14, NS). Thus, elevated CDT levels may be mediated by alcohol severity, distinguishing CDT not only as a marker of heavy drinking, but also as an indicator of the severity of drinking-related biological and psychosocial dysfunction that may require further intervention.
Collapse
Affiliation(s)
- R S Saini
- Center for Studies of Addiction, University of Pennsylvania School of Medicine, Philadelphia 19104-6178, USA
| | | | | | | |
Collapse
|
21
|
Johnson BA, Jasinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, Mason BJ, Bohn MJ, Pettinati HM, Rawson R, Clyde C. Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology (Berl) 1996; 128:206-15. [PMID: 8956382 DOI: 10.1007/s002130050126] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Four hundred and twenty-three alcohol dependent subjects were enrolled into a 12-week randomized, double-blind, placebo-controlled study to determine the safety and efficacy of the 5-HT2 receptor antagonist, ritanserin (2.5 mg/day or 5 mg/day), in reducing alcohol intake and craving. All subjects received 1 week of single-blind placebo prior to randomization into the 11-week double-blind phase. Additionally, all subjects received weekly individual sessions of manual-guided cognitive-behavioral therapy. Comparing the single-blind period with endpoint, there was approximately a 23% reduction in drinks/day; 34% fall in the total number of drinking days/week; 22% decrease in drinks/drinking day; and a 37% diminution in alcohol craving for all treatment groups. All treatment groups experienced a beneficial clinical outcome as assessed by the Clinical Global Impression Scale. There was, however, no significant difference between treatment groups on any of these measures of alcohol drinking, craving, or clinical outcome. Subjects were of relatively high social functioning at baseline, and this did not change significantly during treatment. Treatment groups did not differ significantly on either medication compliance or reported adverse events. Ritanserin treatment was associated with a dose-related prolongation of subjects' QTc interval recording on the electrocardiogram. These results suggest that alcohol dependent subjects can show marked clinical improvement within a structured alcohol treatment program. These findings do not support an important role for ritanserin in the treatment of alcohol dependence.
Collapse
Affiliation(s)
- B A Johnson
- Clinical Laboratory, University of Texas, Health Science Center at Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
There is a great deal of interest in the use of naltrexone as a treatment for alcohol (ethanol) dependence since there is a rapidly expanding body of evidence to support its efficacy and tolerability in this indication. Naltrexone, a long-acting, nonselective opioid receptor antagonist has been shown to reduce alcohol intake when combined with behavioural treatment. Naltrexone may prevent the return to clinically significant drinking by blocking the pleasurable effects or "high' associated with alcohol drinking. Results from controlled studies showed that in alcohol dependent patients taking naltrexone 50 mg/day in combination with behavioural treatment, relapse rates were reduced by 50% compared with placebo treated patients. Historically, several factors have limited the use of effective pharmacological adjuncts in the treatment of alcohol dependence. These include safety considerations in this vulnerable population, and the fact that some treatment programmes discourage alcohol-dependent patients from taking medications. The most common adverse effects reported with the use of naltrexone at a dosage of 50 mg/day include nausea and vomiting. Naltrexone does not appear to be hepatotoxic in dosages recommended in the treatment of alcohol dependence, i.e. 50 mg/day. Thus, naltrexone appears to offer significant therapeutic benefits at a relatively low risk, when used judiciously and with behavioural treatment for alcohol dependent patients.
Collapse
Affiliation(s)
- B J Berg
- Addiction Treatment Research Center, University of Pennsylvania, Philadelphia, USA
| | | | | |
Collapse
|
23
|
Abstract
This study presents a review of existing human studies that examine the role of serotonin [5-hydroxytryptamine (5-HT)] selective agents in the treatment of alcohol dependence. Findings of abnormally low 5-HT levels in many alcohol-dependent patients led investigators to explore the use of 5-HT selective pharmacotherapy in the treatment of alcoholism. Several studies reported that the administration of 5-HT selective pharmacological agents to alcohol-dependent patients effectively reduced alcohol intake, although results have been relatively modest. The most recent study by Kranzler et al. (Am. J. Psychiatry 152:391-397, 1995) found no added benefit over cognitive-behavioral treatment. However, the original relationship between the presence of alcohol dependence and low 5-HT levels in the brains of patients with alcoholism was predicated on subtypes of alcohol dependence. Research has suggested that 5-HT plays an important role in some forms of alcoholism that may be genetically or developmentally mediated. Thus, additional studies are needed to determine if treatment with 5-HT selective agents is viable therapeutic option for alcoholism, specifically in types of alcohol-dependent patients who are most likely to benefit from treatment with 5-HT selective pharmacotherapy.
Collapse
Affiliation(s)
- H M Pettinati
- Addiction Treatment Research Center, University of Pennsylvania, Philadelphia 19104-6178, USA
| |
Collapse
|
24
|
Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, Greenberg R, Rifas SL, Sackeim HA. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 1996; 153:985-92. [PMID: 8678194 DOI: 10.1176/ajp.153.8.985] [Citation(s) in RCA: 287] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
OBJECTIVE Traditionally, it has been widely assumed that the likelihood of response to ECT is independent of the adequacy of previous treatment with antidepressant medications. However, recent research has raised the possibility that medication-resistant patients with depression have a poorer clinical ECT outcome than patients who have not failed previous adequate medication trials. METHOD Medication resistance of 100 patients with primary, unipolar, nonpsychotic major depression was evaluated during the index episode with the Antidepressant Treatment History Form. Patients were recruited and treated with ECT at three sites; standardized ECT and clinical assessment procedures were used. Clinical outcome was assessed immediately and 1 week after completion of the ECT course. RESULTS Patients who previously had failed one or more adequate antidepressant medication trials were less likely to respond to subsequent ECT than patients not known to be medication resistant. This finding held within each study site, whether clinical response was assessed categorically or in terms of the magnitude of symptomatic improvement and after the authors accounted for other potential predictors of clinical outcome. Resistance to heterocyclic antidepressants predicted poorer outcome after ECT, while resistance to selective serotonin reuptake inhibitors and monoamine oxidase inhibitors did not show significant predictive relations. CONCLUSIONS While a substantial percentage of medication-resistant patients respond to ECT, clinical outcome in this group is inferior to that of patients without established medication resistance. The predictive power of medication resistance is generalizable across diverse clinical settings, particularly for heterocyclic antidepressants, which perhaps suggests an overlap in the mechanisms of actions of ECT and this medication class.
Collapse
Affiliation(s)
- J Prudic
- Department of Biological Psychiatry, New York State Psychiatric Institute, NY 10032, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Pettinati HM, Belden PP, Evans BD, Ruetsch CR, Meyers K, Jensen JM. The natural history of outpatient alcohol and drug abuse treatment in a private healthcare setting. Alcohol Clin Exp Res 1996; 20:847-52. [PMID: 8865959 DOI: 10.1111/j.1530-0277.1996.tb05262.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Managed healthcare has had a major impact on the delivery of alcohol and drug abuse treatment services in the private setting, primarily by shifting patient enrollment from inpatient to outpatient treatment programs. The purpose of this study was to investigate the natural history of outpatient alcohol and drug abuse treatment in a private, nonprofit healthcare setting. Patient profiles at pretreatment, their attendance record in a 6-week outpatient program, and their outcome in the year after treatment were evaluated in 120 patients with a DSM-III-R diagnosis of alcohol and/or cocaine dependence. There were 70 outpatients who successfully completed the program, and 50 who did not. Two subtypes of outpatient treatment failures were identified: S5 who prematurely left treatment against medical advice (n = 23), and S8 who attended treatment but continued heavy use of substances (Treatment Resistant, n = 27). A logistic regression revealed that younger age, multiple prior treatments, and employment problems were related to outpatient treatment failure. Outpatient failures did not immediately seek alternative treatment, and most of them continued heavy substance use in the year post-treatment: i.e., 82% vs. 43% successful completers (chi 2 = 13.8, df = 1, p < 0.01). Thus, there were a clinically relevant number of outpatient failures (42%), either because of lack of program attendance or continued substance use throughout treatment. These behaviors were related to continued heavy use of substances in the year after treatment.
Collapse
Affiliation(s)
- H M Pettinati
- Research Division, Carrier Foundation, Belle Mead, New Jersey, USA
| | | | | | | | | | | |
Collapse
|
26
|
Meyers K, McLellan AT, Jaeger JL, Pettinati HM. The development of the Comprehensive Addiction Severity Index for Adolescents (CASI-A). An interview for assessing multiple problems of adolescents. J Subst Abuse Treat 1995; 12:181-93. [PMID: 7474026 DOI: 10.1016/0740-5472(95)00009-t] [Citation(s) in RCA: 131] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The Comprehensive Addiction Severity Index for Adolescents (CASI-A) is a 45 to 90-minute comprehensive, semi-structured clinical interview for evaluating adolescents who present for treatment at various provider agencies. CASI-A modules and their individual items were selected and revised based on theory, clinical wisdom, and adolescent experiences obtained during pilot interviews and focus groups. The CASI-A assesses known risk factors, concomitant symptomatology, and consequences of adolescent alcohol/drug use within seven primary areas of functioning: education status, alcohol/drug use, family relationships, peer relationships, legal status, psychiatric distress, and use of free time. The CASI-A is not a diagnostic or screening instrument, but rather a clinical assessment tool that obtains clinically pertinent information designed to guide treatment planning and to evaluate treatment outcome. The CASI-A's design makes it suitable for administration in a variety of settings, for repeat administration at posttreatment follow-up evaluations, and for assessment of virtually all adolescents in treatment regardless of their admission problem. Overall, the CASI-A has encouraging but preliminary evidence of validity and internal consistency. Information collected soon after admission during administration of the CASI-A by nonclinical interviewers corresponded quite well with that obtained over the course of the adolescent's treatment stay by the entire treatment team. Revisions to the instrument are being made in those areas where correspondence between information on the CASI-A and that extracted from clinical records dropped below 75%, or in those early subscales, where alpha coefficients dropped below .6. As a result of the encouraging results reported in this paper, we are beginning additional psychometric testing, refining the proposed scoring system, and developing a computerized data entry, scoring, and report system.
Collapse
Affiliation(s)
- K Meyers
- University of Pennsylvania/VA Center for Studies of Addiction, Philadelphia, USA
| | | | | | | |
Collapse
|
27
|
Pettinati HM. Speed of ECT? Convuls Ther 1994; 10:69-72. [PMID: 8055294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
28
|
Abstract
Miller and Hester's 1986 review of inpatient versus outpatient alcohol treatment studies concluded with no "justification" for inpatient treatment. Further examination of these studies revealed shortcomings such as the use of random assignment designs which excluded psychiatrically-complicated patients. Carrier Foundation's inpatient/outpatient study of private psychiatric patients with alcohol and/or cocaine dependence includes a patient-treatment matching design to address weaknesses in the existing literature. Patients with high psychiatric severity and/or a poor social support system are predicted to have a better outcome in inpatient treatment, while patients with low psychiatric severity and/or a good social support system may do well as outpatients without incurring the higher costs of inpatient treatment. Preliminary results from 183 inpatients and 120 outpatients indicated outpatients, regardless of level of psychiatric severity, were 4 times more likely to be early treatment failures (chi-square = 41.2, df = 1, p < .01). While the determination of long-term follow-up status of early treatment failures is currently underway, this finding underscores the potential risk of early treatment failure in outpatient compared to inpatient substance abuse treatment programs and the importance of addressing the issue of early attrition in conducting outcome analyses.
Collapse
|
29
|
Stephens SM, Greenberg RM, Pettinati HM. Choosing an electroconvulsive therapy device. Psychiatr Clin North Am 1991; 14:989-1006. [PMID: 1771159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The selection of an electroconvulsive therapy (ECT) device from the more than 10 American-made models can be a difficult endeavor. This article is meant to be a single source of basic descriptions of these ECT devices. The information provided will allow the ECT clinician to be aware of the important issues involved in the selection of an ECT device and to become familiar with the basic features of each model.
Collapse
Affiliation(s)
- S M Stephens
- Carrier Foundation Research Division, Belle Mead, New Jersey
| | | | | |
Collapse
|
30
|
Abstract
Among 48 patients with diagnoses of depression according to DSM-III, there was a significant relation between therapeutic failure of unilateral ECT, as measured by scores on the Hamilton Rating Scale for Depression, and the concomitant use of a benzodiazepine. Of the 34 patients who showed a good therapeutic response to unilateral ECT, those taking benzodiazepines had smaller changes in their Hamilton depression ratings from before treatment to after treatment and were more symptomatic at the end of the course of ECT. Thus, when patients take benzodiazepines during a course of unilateral ECT, the maximum therapeutic response may be compromised.
Collapse
Affiliation(s)
- H M Pettinati
- Research Division, Carrier Foundation, Belle Mead, NJ 08502
| | | | | | | |
Collapse
|
31
|
Abstract
Data on the hypnotizability of 113 psychiatric inpatients and 58 normal control subjects were compared. The patients' mean score on the Hypnotic Induction Profile was significantly lower than that of the control subjects, but on the Stanford Hypnotic Susceptibility Scale: Form C, these patients and control subjects did not differ significantly. On both scales rank-ordered scores of different diagnostic groups of the patients supported the theory that hypnotizability varies according to type of psychopathology. Some results, such as the hypnotizability of the schizophrenic patients, depended on which scale was used. This finding may explain the conflicting literature on the hypnotic potential of schizophrenic patients.
Collapse
Affiliation(s)
- H M Pettinati
- Research Division, Carrier Foundation, Belle Mead, NJ 08502
| | | | | | | | | | | |
Collapse
|
32
|
Abstract
This study investigated whether occupational class is related to the severity of problems associated with alcohol abuse in females. Sixty-six female alcoholic inpatients at a private psychiatric hospital were studied. Of these women, 31 were workers (working at the time of admission), 18 were unemployed workers (unemployed at admission but had worked most of their adult lives), and the remaining 17 were homemakers. Problem severity was assessed for 66 alcoholic women using the Addiction Severity Index (ASI), a standardized clinical interview. A questionnaire assessing the degree of occupational stress experienced was also administered. Employment problem severity ratings from the ASI differed significantly across the three occupation subgroups [F(2,63) = 10.99, p less than .05]; the unemployed workers reported more severe employment problems than did either the workers [t(63) = 3.07, p less than .05] or homemakers [t(63) = 4.77, p less than .05]. There were no significant differences between the three groups on the other five ASI dimensions. A cluster analysis on ASI severity ratings revealed a trend for workers to have family and psychological problems in addition to alcoholism. This seems not to have had an impact on wanting a job change; significantly more homemakers (z = 4.77, p less than .05) and unemployed workers (z = 4.56, p less than .05) than workers wanted a job change.
Collapse
|
33
|
Kight-Law A, Sugerman AA, Pettinati HM. An application of an MMPI classification system for predicting outcome in a small clinical sample of alcoholics. Am J Drug Alcohol Abuse 1988; 14:325-34. [PMID: 3189255 DOI: 10.3109/00952998809001554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The purpose of this study was to apply Conley and Prioleau's MMPI classification system to predict drinking and adjustment outcome for a sample of 113 inpatient alcoholics. Although a dual grouping (termed "reactive" and "essential") of the original six MMPI subtypes was found to be more useful for this sample size, the findings, nevertheless, supported the predictive value of this MMPI classification system. The "essential" group, derived from a triad of Psychopathic and Schizoform MMPI types was rated as drinking significantly more often during 4 years after treatment than the "reactive" group, derived from a triad of Neurotic and Classic MMPI types (Fisher's p = .02). Females classified as the "essential" MMPI group were rated as having significantly poorer adjustment (Fisher's p = .007) than females classified as the "reactive" MMPI group.
Collapse
Affiliation(s)
- A Kight-Law
- Carrier Foundation, Belle Mead, New Jersey 08502
| | | | | |
Collapse
|
34
|
Pettinati HM, Franks V, Wade JH, Kogan LG. Distinguishing the role of eating disturbance from depression in the sex role self-perceptions of anorexic and bulimic inpatients. J Abnorm Psychol 1987. [PMID: 3479485 DOI: 10.1037//0021-843x.96.3.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
35
|
Pettinati HM, Franks V, Wade JH, Kogan LG. Distinguishing the role of eating disturbance from depression in the sex role self-perceptions of anorexic and bulimic inpatients. Journal of Abnormal Psychology 1987; 96:280-2. [PMID: 3479485 DOI: 10.1037/0021-843x.96.3.280] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
36
|
Pettinati HM, Wade JH. Hypnosis in the treatment of anorexic and bulimic patients. Semin Adolesc Med 1986; 2:75-9. [PMID: 3602628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
37
|
Horne RL, Pettinati HM, Sugerman AA, Varga E. Comparing bilateral to unilateral electroconvulsive therapy in a randomized study with EEG monitoring. Arch Gen Psychiatry 1985; 42:1087-92. [PMID: 3901956 DOI: 10.1001/archpsyc.1985.01790340065010] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
In a double-blind study, 48 DSM-III depressed patients were randomly assigned to either the bilateral or nondominant unilateral electroconvulsive therapy (ECT) group. Seizure length was monitored by electroencephalography (EEG). When seizures were less than 25 s, ECT was immediately readministered. When length of seizure and pretreatment depression scores were controlled between the two groups, there were no differences in treatment effectiveness, as measured by the Hamilton Rating Scale for Depression and the Beck Depression Inventory, or in the number of treatments required. This was true after five ECT treatments as well as after completing all ECT treatments. Thus, when ECT is monitored via EEG to assure the presence of an adequate seizure, bilateral and nondominant unilateral placement yield equivalent responses. If ECT had not been readministered immediately following a missed seizure, unilateral patients would have had significantly more missed seizures. Significant difficulties in both short- and long-term memory were found 24 hours after the fifth ECT in bilateral but not in nondominant unilateral patients. No apparent memory loss could be documented in nondominant unilateral ECT.
Collapse
|
38
|
Abstract
Hypnotizability was assessed with the use of three standardized hypnosis scales in 86 patients with eating disorders. All diagnoses were made according to DSM-III criteria. Sixty-five patients had anorexia nervosa and 21 had bulimia. The anorectic patients were divided into subgroups of 19 abstainers and 46 vomiters and purgers. Bulimic patients were highly hypnotizable, significantly more so than the patients with anorexia nervosa and age-matched populations. There was also a trend for the purging subgroup of anorectics to have higher hypnotic capacity than abstaining anorectics.
Collapse
|
39
|
Pettinati HM, Brown MM. Assessing depression in evaluating memory impairment. J Am Geriatr Soc 1985; 33:570-1. [PMID: 4020003 DOI: 10.1111/j.1532-5415.1985.tb04626.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
40
|
Abstract
The number of electroconvulsive therapy (ECT) stimulations over a course of treatment that resulted in brief or no seizure activity was evaluated for depressed patients (N = 58, treated for DSM-III diagnosed major depressive disorder) who had been randomly assigned to either bilateral or unilateral nondominant ECT in a double-blind study. Comparable treatment efficacy between both groups was found. Although there were no group differences in brief seizures, unilateral nondominant ECT resulted in more missed seizures (p less than 0.01) and required more restimulations than bilateral ECT. Of 27 unilateral ECT patients, 63% had at least one missed seizure over the course of treatment, compared to 29% of 31 bilateral ECT patients (p less than 0.02). Although more missed seizures occurred early in treatment, brief seizures occurred later in treatment. As missed seizures are not always detected clinically, it is possible that without seizure monitoring, patients with unilateral nondominant ECT will not improve at the same rate as patients with bilateral ECT. Lack of seizure monitoring in the clinic is one likely explanation for the discrepancy between a number of research studies reporting equivalent efficacy for bilateral and unilateral ECT and the clinical impression that bilateral ECT is more effective.
Collapse
|
41
|
|
42
|
Abstract
Retrospective and outcome data were examined for 48 homemaking and 24 working women who came for treatment for alcoholism to an Addiction Recovery Unit at an inpatient psychiatric hospital. Outcome was assessed at the end of each of 4 years following treatment via personal interview by an experienced social worker and was corroborated by at least one source. At admission, the homemakers had been drinking for significantly more years (p less than 0.05) than working women. Occupation at admission did not directly relate to outcome. However, for a small subgroup comprised of both homemaking and working women, a change in occupation following treatment was associated with improvement.
Collapse
|
43
|
Abstract
A structured interview was used to elicit 35 depressed patients' reports of memory function after a full course of either bilateral or unilateral ECT. The interviewer and patients were blind to the type of electrode placement. Although the two groups of subjects did not differ in severity of depression or amount of ECT, significantly more patients receiving bilateral ECT reported general difficulty remembering things, difficulty describing events before hospitalization, and difficulty remembering daily events.
Collapse
|
44
|
Pettinati HM, Rosenberg J. Memory self-ratings before and after electroconvulsive therapy: depression-versus ECT induced. Biol Psychiatry 1984; 19:539-48. [PMID: 6733173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The Squire Self-rating Scale of Memory Function was administered to 28 depressed inpatients before and after electroconvulsive therapy (ECT), with random assignment to bilateral or unilateral electrode placement. Several memory changes differentiated between bilateral and unilateral ECT following treatment (p less than 0.05). Memory complaints arising from ECT were distinguished from those due to depression.
Collapse
|
45
|
Abstract
Cognitive functioning in depressed geriatric patients, some with a history of ECT, was assessed with the Trail Making B test. Depressed patients over the age of 65 who had had at least one prior series of ECT performed more poorly on the test than did older patients with no history of ECT and younger depressed patients regardless of their ECT history. The groups did not differ in severity of depression. Careful assessment of elderly patients' history of ECT will allow for more informed decisions about the current use of ECT and an understanding of the cognitive status of these patients.
Collapse
|
46
|
Horne RL, Pettinati HM, Menken M, Sugerman AA, Varga E, Wilson GF. Dexamethasone in electroconvulsive therapy: efficacy for depression and post-ECT amnesia. Biol Psychiatry 1984; 19:13-27. [PMID: 6704458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Dexamethasone, compared to placebo in a double-blind study, failed to prevent the memory deficiency that typically accompanies electroconvulsive therapy (ECT) (n = 48 patients treated for DSM-III diagnosed major depressive disorder). Rather, the administration of the drug was associated with attention (p less than 0.02) and short-term memory (p less than 0.0003) difficulties in both bilateral and unilateral ECT patients. Bilateral ECT plus dexamethasone patients had significantly less improvement (p less than 0.05) in their depression (measured by the Hamilton Depression Scale) compared to bilateral ECT plus placebo patients. These depression differences were not seen among unilateral ECT patients.
Collapse
|
47
|
|
48
|
Abstract
Alcoholic patients completed the Minnesota Multiphasic Personality Inventory (MMPI) while hospitalized for treatment and again after 4 years of follow-up. Those who remained abstinent and functioned well in the community for the 4-yr period were characterized during treatment by a significant elevation on the Depression (D) scale which decreased to normal ranges at follow-up. Those who continued to drink periodically over the 4-yr period had initial peaks on Psychopathy (Pd) and Hypomania (Ma) which were still elevated at follow-up. An intermediate group who were usually abstinent during the 4-yr period but had occasional relapses showed elevations on D and Pd during treatment with return to normal levels at follow-up.
Collapse
|
49
|
Pettinati HM, Sugerman AA, DiDonato N, Maurer HS. The natural history of alcoholism over four years after treatment. J Stud Alcohol 1982; 43:201-15. [PMID: 7120992 DOI: 10.15288/jsa.1982.43.201] [Citation(s) in RCA: 70] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
50
|
|